GlassScriptPhysician profile
Parikshit Deshmukh
NPI 1437395845
$344,406.40
in general payments reported to CMS, 2019-2025
11 companies · $76.46 in 2025
The $76.46 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159K · 2020: $30K · 2021: $45K · 2022: $34K · 2023: $68K · 2024: $7,092 · 2025: $76.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Consulting Fee: $7,338 · Food and Beverage: $3,035 · Travel and Lodging: $2,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,683.50 |
| Consulting Fee | $7,338.00 |
| Food and Beverage | $3,034.63 |
| Travel and Lodging | $2,204.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $158,053.71 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $91,826.40 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $58,099.74 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $21,182.88 | 2019-2024 | Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $14,631.12 | 2022-2024 | Nuedexta, Rexulti |
| Janssen Pharmaceuticals, INC | $348.87 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $149.61 | 2021-2022 | |
| Urovant Sciences INC | $61.72 | 2021-2022 | |
| Mdd US Operations, LLC | $19.96 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $16.78 | 2021 | |
| Sun Pharmaceutical Industries INC. | $15.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parikshit Deshmukh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.